There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Indaptus Therapeutics (INDP – Research Report) and Achieve Life Sciences (ACHV – Research Report) with bullish sentiments.
Indaptus Therapeutics (INDP)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Indaptus Therapeutics yesterday and set a price target of $4.00. The company’s shares closed last Tuesday at $2.54.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
Indaptus Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.00, implying a 220.0% upside from current levels. In a report issued on August 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Achieve Life Sciences (ACHV)
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Achieve Life Sciences today and set a price target of $35.00. The company’s shares closed last Tuesday at $5.19.
According to TipRanks.com, Higgins is a 3-star analyst with an average return of
Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $24.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INDP:
- Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Indaptus Therapeutics reports Q2 EPS (39c) vs (46c) last year
- Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20
- Indaptus Therapeutics announces opening of next cohort in trial of Decoy20
- Indaptus Therapeutics appoints Waltzman as Chief Medical Officer
